---
layout: default
title: Minoxidil
parent: 僅模型預測 (L5)
nav_order: 92
evidence_level: L5
indication_count: 10
---

# Minoxidil
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Minoxidil (DB00350): Drug Profile Report — No Repurposing Predictions Available

---

## One-Sentence Summary

Minoxidil (DB00350) is a well-known potassium channel opener with established global use for hypertension and androgenetic alopecia, but holds **zero registered licenses in Taiwan**.
This Evidence Pack returned **no TxGNN repurposing predictions** — critical data fields (mechanism of action, regulatory indication text) were not populated, preventing prediction generation.
A **Hold** decision is recommended until all data gaps are resolved and the prediction pipeline is re-executed.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in this Evidence Pack |
| Predicted New Indication | No prediction generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A — prediction pipeline not completed |
| Taiwan Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why No Predictions Were Generated

The Evidence Pack for Minoxidil is missing two critical data fields required before TxGNN can produce repurposing predictions:

**1. Mechanism of Action (MOA) — Data Gap DG002 (Severity: High)**
TxGNN relies on pharmacological mechanism embeddings to compute similarity between a drug's known targets and candidate disease nodes in the knowledge graph. Without MOA data, the model cannot establish mechanistic linkages, and any score produced would be unreliable.

**2. Taiwan Regulatory Indication Text — Data Gap DG001 (Severity: Blocking)**
The TFDA query returned zero results (0 licenses), meaning there is no approved indication text to anchor the drug's therapeutic category within the pipeline. This gap is classified **Blocking**, which halts the safety screening step (S1) entirely.

> **Note on query log anomaly:** The DrugBank source query (Log ID 3) returned `result_status: success` with `result_count: 1`, yet no drug-level fields (MOA, warnings, categories) were populated in the Evidence Pack. This suggests a **data pipeline parsing issue** — the API call succeeded but the response was not correctly mapped. This should be investigated before re-running.

---

## Data Gaps to Resolve

| Gap ID | Item | Severity | Impact | Remediation |
|--------|------|----------|--------|-------------|
| DG001 | Taiwan regulatory warnings / contraindications | **Blocking** | Cannot enter S1 safety screening | Download TFDA package insert PDF and parse warnings section |
| DG002 | Mechanism of Action (MOA) | **High** | Cannot run mechanistic linkage analysis | Investigate DrugBank API response parsing; re-populate MOA field |

---

## Safety Considerations

All safety fields returned in this Evidence Pack are empty or flagged as data gaps. Please refer to the original package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Minoxidil's Evidence Pack is structurally incomplete — a Blocking-severity data gap (DG001) halts safety screening, and a High-severity gap (DG002) prevents mechanistic analysis. No TxGNN predictions were generated, making a repurposing evaluation impossible at this stage.

**To proceed, the following is needed:**

- **Investigate DrugBank pipeline parsing bug:** API call (Log ID 3) returned success with count=1, but zero fields were populated — identify the mapping failure and re-extract MOA, drug categories, and toxicity data
- **Resolve DG001:** Download and parse TFDA package insert PDF to retrieve approved indications, warnings, and contraindications
- **Re-run TxGNN prediction pipeline** after both data gaps are resolved
- **Verify Taiwan market status independently:** Confirm whether Minoxidil topical/oral products exist under any brand name in the TFDA database, as the drug is widely marketed in other regions
## Ansvarsfriskrivning

Detta innehåll är endast avsett för forskningsändamål och utgör inte medicinsk rådgivning.
Klinisk validering krävs före klinisk tillämpning.

---

